ProThera Biologics
Latest round
- Series A
Last raised
- Sep 2012
Total raised
- $0.8M
Investors
- 1
About ProThera Biologics
ProThera Biologics Inc., headquartered in East Providence, US, focuses on therapeutic solutions for severe inflammatory conditions. The company has undergone no major pivots in its business strategy and operates independently. Its founder's background details are not publicly available.ProThera Biologics focuses on developing innovative therapeutic solutions for severe inflammatory diseases through a specialized class of human plasma proteins known as Inter-alpha inhibitor proteins (IAIP). These proteins play a critical role in controlling inflammation by modulating various immune pathways, which is paramount in addressing life-threatening immune responses that often lead to high mortality rates in affected patients. By harnessing the natural anti-inflammatory properties of IAIP, ProThera aims to restore immune regulation and improve patient health outcomes, particularly for those who are admitted to Intensive Care Units and face significant health risks due to uncontrolled inflammation.ProThera Biologics generates revenue primarily through partnerships with healthcare institutions and pharmaceutical companies that seek to utilize its innovative IAIP-based therapies. The company's business model involves B2B transactions, where it collaborates with hospitals and clinics to provide its life-saving medications. By engaging in agreements for the supply of IAIP therapies, ProThera establishes pricing structures based on the specific treatment regimens required by patients. The financial transactions are structured to accommodate the needs of healthcare providers, potentially involving per-treatment fees or volume-based pricing that reflect the scale of usage within healthcare settings.ProThera Biologics is focused on expanding its product pipeline with new therapies designed to enhance the treatment of severe inflammatory diseases. Furthermore, ProThera aims to extend its market reach into Europe and Asia, targeting healthcare providers that require advanced therapeutic solutions for critical care patients.
Who invested in ProThera Biologics
1 investor across 3 rounds
See all investors in ProThera Biologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ProThera Biologics
Who invested in ProThera Biologics?
ProThera Biologics has 1 investor on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ProThera Biologics raised?
ProThera Biologics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did ProThera Biologics last raise money?
ProThera Biologics's most recent round on record is a Series A, in Sep 2012.
What does ProThera Biologics do?
ProThera Biologics is a biotechnology company.
Where is ProThera Biologics headquartered?
ProThera Biologics is headquartered in East Providence, US.
Which VCs invest in companies like ProThera Biologics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ProThera Biologics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ProThera Biologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.